TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04358627

Intervention type: DRUG
Intervention: Dexmedetomidine Injectable Product
Description: continuous intravenous infusion of dexmedetomidine
Study: NCT02463487

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardinal Pro +Simultaneous Irrigation (NPWTi)
Description: NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardinal Pro (NPWT) Therapy
Description: NPWT 125 mm Hg continuous pressure with foam interface
Study: NCT03263390

Intervention type: DRUG
Intervention: Anti Obesity Drugs
Description: Response to FDA approved anti obesity medications
Study: NCT01345942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5428029
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5428029
Description: Single oral dose
Study: NCT03571594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5788
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5788
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5788 Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5788 Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5788 Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5788 Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5788 Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Active Comparator in Part D
Study: NCT04435886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic mixture with maltodextrin as a carrier.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator with maltodextrin as a carrier.
Study: NCT03583710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitotane
Description: Given PO
Study: NCT03367741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01176344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo capsules once monthly for 2 years.
Study: NCT03946358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Four blood samples will be collected at:~* baseline~* 2 months from inclusion (+/- 1 week)~* 4 months from inclusion (+/- 1 week)~* the end of vaccination visit (+/- 1 week).~A total of 8 EDTA (ethylenediaminetetraacetic acid) tubes of 6 ml will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: One 6 ml EDTA tube should be frozen in each investigation center for ctDNA collection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsies
Description: A tumor biopsy will be realized and centralized at baseline and at 2 months. Collection of tumor biopsies will be guided by ultrasound or CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT scan
Description: A CT scan will be planned~* at baseline~* at tumor evaluation visit (8 weeks)~* every 8 weeks (+/- 1 week)~* at end of treatment visit.
Study: NCT03583710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitotane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03946358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Induction phase: Atezolizumab 1200 mg intravenous every 3 weeks since day 1~Boost phase: Atezolizumab 1200 mg intravenous every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax
Description: Induction phase: UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase: UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5).
Study: NCT03583710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04204902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 100 mg
Description: Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in either treatment period 1 or 2.
Study: NCT04204902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 100 mg
Description: Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in either treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 250 mg
Description: Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in either treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 250 mg
Description: Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in either treatment period 1 or 2.
Study: NCT03115515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Description: To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Description: To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
Study: NCT02514746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
Description: 0.5 mL subcutaneous injection
Study: NCT02372357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole prophylaxis 120 mg/m² tid
Description: Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
Study: NCT03308331

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco smoking and nicotine patch
Description: Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco smoking and nicotine patch
Description: Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco smoking and nicotine patch
Description: Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco smoking and nicotine patch
Description: Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
Study: NCT04106635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Description: To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cricoid pressure
Description: To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
Study: NCT01800110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Study: NCT03607500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric intake reduction
Description: The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
Study: NCT00938080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG013
Description: Mouth rinse once a day for 14 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG013
Description: Mouth rinse three times a day for 14 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG013
Description: Mouth rinse six times a day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinse once a day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinse three times a day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinse six times a day for 14 days
Study: NCT02714842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled Diclofenac Tablet A
Description: Delayed release diclofenac sodium tablet (50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled Diclofenac tablet B
Description: Delayed release diclofenac sodium tablet (50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled Diclofenac tablet C
Description: Delayed release diclofenac sodium tablet (25 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Enteric coated delayed release diclofenac sodium tablet (50 mg)
Study: NCT02176759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of rice fortified with regular FePP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of rice fortified with regular FePP with citrate added during extrusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of rice fortified with regular FePP and citrate added at consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of rice fortified with ferrous sulphate
Study: NCT02645370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danzhen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Study: NCT02688166

Intervention type: OTHER
Intervention: Complete Cardiac Magnetic Resonance Imaging (MRI)
Description: Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy

Intervention type: OTHER
Intervention: Complete Cardiac Magnetic Resonance Imaging (MRI)
Description: Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
Study: NCT02269774

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard pulmonary vein isolation
Description: The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
Study: NCT00802503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SPN
Description: SPN : in the treated group, SPN is started if at day 4 energy input by EN is \< 60% of energy target in order to reach 100% of energy target by peripheral or central line.
Study: NCT01177358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
Study: NCT05197374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate 4mg
Description: Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
Study: NCT03743142

Intervention type: PROCEDURE
Intervention: endovascular repair of the AAA
Description: The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
Study: NCT00498966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food.
Study: NCT03615274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Executive function training
Description: Home-based executive function training with adaptive difficulty, through Cogmed and Cognifit systems over 6 weeks (30-45 minuts/day, 5 days per week). Cognitive training will consist on working memory training (Cogmed, www.cogmed.com) and executive/inhibitory function training (Cognifit, www.cognifit.com).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Learning basic healthy habits through daily Prezi presentations that include healthy food recommendations, funny receipts to families, ideas for exercising, emotion and behavioral management strategies, etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Learning basic healthy habits through daily Prezi presentations that include healthy food recommendations, funny receipts to families, ideas for exercising, emotion and behavioral management strategies, etc.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo non-adaptive training
Description: Executive function training with non-adaptive difficulty through Cognifit system over 6 weeks (30-45 minuts/day, 5 days per week). Exercices will be the same as the ones in the experimental group but minimizing the executive/working memory component and without incresing difficulty.
Study: NCT03749018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00974298

Intervention type: PROCEDURE
Intervention: Total elbow replacement arthroplasty
Description: Total elbow arthroplasty using pressfit technique in which no cement is used.
Study: NCT02141581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (IM)
Description: This vaccine is given intramuscularly (IM)
Study: NCT06704646

Intervention type: PROCEDURE
Intervention: Curative intent surgery
Description: Curative intent surgery means that surgeons intend to perform R0 resection.

Intervention type: PROCEDURE
Intervention: Curative intent surgery
Description: Curative intent surgery means that surgeons intend to perform R0 resection.
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 liquid capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 liquid capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 liquid capsules
Description: Oral capsules
Study: NCT02141581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Intradermal (ID)
Description: This vaccine is given intradermally (ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2011-2012 FluMist®
Description: This vaccine is given intranasally
Study: NCT01932944

Intervention type: DEVICE
Intervention: No treatment
Study: NCT02662738

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural fruit extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose solution
Study: NCT06109532

Intervention type: OTHER
Intervention: hyponatremia
Description: hyponatremia at admission in dengue infected patients

Intervention type: OTHER
Intervention: hyponatremia
Description: hyponatremia at admission in dengue infected patients

Intervention type: OTHER
Intervention: hyponatremia
Description: hyponatremia at admission in dengue infected patients
Study: NCT00556543

Intervention type: DEVICE
Group type: OTHER
Intervention: U-plate fracture repair system
Description: All subjects meeting inclusion criteria will undergo surgery for the repair of their fractured rib/s using the U-plate device. Subjects will be monitored daily during the entire course of their hospitalization for adverse experiences. Subjects will be contacted by phone to complete the MPQ and SF-36 Health Survey. Subjects will be asked if and when they have returned to work or to their previous level of functioning. Subjects will be asked if they had any complications or problems associated with their surgery.
Study: NCT00503074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV modification
Description: Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: safety and injury prevention
Description: Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
Study: NCT02681276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigation with 3% NaOCl
Description: All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation with 0.5% NaOCl
Description: All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
Study: NCT06103422

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole mouth taste tests
Description: Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering whole mouth taste tests. In the whole mouth taste test, one ml of the specific solution was drawn into the syringe and sprayed into the mouth of the patient circularly. After each administration, patients spat out the solutions and reported whether they perceived any taste and, if so, which taste it was.
Study: NCT02883439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP29-02
Description: local nasal application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: local nasal application
Study: NCT01781234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01402128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barley beta-glucan(3.0g)
Description: Barley beta-glucan(3.0g/day) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study: NCT02505035

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Default ordering of palliative consult